Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Chief Medical Officer | May 05, 2026 | May 07, 2026 |
| eFFECTOR Therapeutics, Inc.EFTR · Entity 89916 | Chief Medical Officer | February 19, 2024 | February 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tyra Biosciences, Inc.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2026-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 25,000 · Balance 25,000 F1: Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2: Includes RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.93 · Expires 2036-05-04 | Direct | 85,000 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Grant · Acquired 85,000 · Balance 85,000 F3: 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: Includes RSUs.
F3: 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
eFFECTOR Therapeutics, Inc.
Report date February 19, 2024 · Filed February 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.32 · Expires 2034-02-18 | Direct | 25,000 |
Reported balance
After 2024-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-19 · Grant · Acquired 25,000 · Balance 25,000 F1: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of February 19, 2024 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of February 19, 2024 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2026 Filed May 7, 2026 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $33.93 | $0.00 |
DisclosureSEC source: 0001193125-26-212116 · ownership.xml · derivative · entry 2 Warner Douglas J · CIK 0001941311 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2036-05-04 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-212116 · ownership.xml · nonDerivative · entry 1 Warner Douglas J · CIK 0001941311 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes RSUs. Read SEC document |
| August 07, 2025 Filed Aug 7, 2025 20:38 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0000950170-25-105132 · ownership.xml · derivative · entry 1 Warner Douglas J · CIK 0001941311 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-08-06 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on August 7, 2026, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 20:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0000950170-24-105200 · ownership.xml · derivative · entry 1 Warner Douglas J · CIK 0001941311 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2034-09-08 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on September 9, 2025, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| February 19, 2024 Filed Feb 21, 2024 22:00 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-24-003673 · doc4.xml · derivative · entry 1 Warner Douglas J · CIK 0001941311 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-02-18 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of February 19, 2024 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:07 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-23-004050 · doc4.xml · derivative · entry 1 Warner Douglas J · CIK 0001941311 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-01-16 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 17, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| August 08, 2022 Filed Aug 8, 2022 22:17 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 618,160 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-22-044874 · doc4.xml · derivative · entry 1 Warner Douglas J · CIK 0001941311 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,160 Underlying: Common Stock · 618,160 shares Expires 2032-08-07 F1 · derivative.exercise_date: The stock option vests 25% on August 8, 2023, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.